Henry Schein, IncNasdaq: HSIC
Health Care · Health Care Distributors
$81.88
+11.40%
Vol: 60K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Henry Schein announced major board restructuring on May 21, reducing directors from 15 to 10 with founder Stanley Bergman retiring after 44 years and being named Chairman Emeritus.Mixed▶
On May 21, 2026, Henry Schein announced its plan to reduce its Board of Directors from fifteen to ten members following its 2026 Annual Meeting. Founder Stanley M. Bergman retired from the Board after 44 years as a director and was designated Chairman Emeritus, while Joseph L. Herring, Robert J. Hombach, Scott Serota, and Bradley T. Sheares did not stand for reelection. Earlier in May, Henry Schein reported strong Q1 2026 results with adjusted EPS of $1.32 versus $1.20 consensus, revenue of $3.37 billion (up 6.3% YoY), and raised full-year guidance to $13.6-$13.8B revenue and $5.23-$5.37 EPS. The company also completed a multi-year share repurchase program totaling 43.30 million shares for ~$3.10B. However, analyst price targets were cut at multiple firms including Baird to $97 from $104, Mizuho to $82 from $88, and UBS to $85 from $87.
May 20Henry Schein beats Q1 estimates, lifts 2026 guidance, and announces longtime Chairman Stanley Bergman's retirement.Positive▶
Henry Schein reported Q1 2026 results on May 5 with adjusted EPS of $1.32 (vs. $1.20 consensus) and revenue of $3.37B (up 6.3% YoY), beating estimates. Non-GAAP diluted EPS rose 14.8% YoY. Management raised full-year 2026 guidance to revenue of $13.6B-$13.8B and EPS of $5.23-$5.37. The company announced longtime Chairman Stanley M. Bergman will retire from the Board after 44 years following the May 21 annual meeting, becoming Chairman Emeritus. The board will be reduced in size. Dental and technology strength offset medical softness due to a weak flu season. Despite the beat, Baird cut its PT to $97 (from $104), Mizuho to $82 (from $88), and UBS to $85 (from $87). The Henry Schein One 2026 Catalyst Index released May 14 emphasizes clinical execution as the key growth driver.
May 19Henry Schein Q1 2026 sales rose 6.3% to $3.37B with non-GAAP EPS of $1.32 beating by 8.4%; reaffirms FY26 EPS guidance of $5.23-$5.37.Mixed▶
Henry Schein reported Q1 2026 net sales of $3.37 billion (up 6.3% YoY) with GAAP diluted EPS of $0.92 and non-GAAP EPS of $1.32 (up 14.8% YoY, beating $1.20 consensus by 8.4%), driven by strong dental and technology results that offset medical softness from a weak flu season. The company reaffirmed 2026 non-GAAP EPS guidance of $5.23-$5.37 and total sales growth of 3-5%, targeting $125 million in savings by year-end via AI and operational efficiency. On May 21, the company will reduce its board from 15 to 10 members following the annual meeting, with Stanley M. Bergman retiring after 44 years and being designated Chairman Emeritus. Despite the earnings beat, analyst targets were trimmed broadly: Baird to $97 (from $104), Mizuho to $82 (from $88), and UBS to $85 (from $87). The 30-day share price return is -6.07%.
May 18Henry Schein shares rose 4.5% to $72.61 on May 14 as Henry Schein One released its 2026 Catalyst Index ahead of the May 21 annual meeting and board reduction.Positive▶
Henry Schein Inc shares climbed 4.5% on May 14, 2026 to $72.61 following the release of Henry Schein One 2026 Catalyst Index, the fifth edition of its annual benchmarking report, revealing that growth in a slower economy is driven by clinical execution rather than scale, with top performers achieving 75% case acceptance vs. 45% for the average practice. The board will be reduced to 10 directors following the May 21, 2026 Annual Meeting, with Stanley M. Bergman retiring from the board after 44 years as a director and being designated Chairman Emeritus. Joseph L. Herring, Robert J. Hombach, Scott Serota, and Bradley T. Sheares will not stand for reelection. Q1 2026 results posted May 5 showed net sales of $3.37B (up 6.3% YoY) and non-GAAP EPS of $1.32 beating estimates. The board overhaul and operational momentum drove the bounce.
May 15Henry Schein jumped 4.5% to $72.61 after Q1 sales rose 6.3% and insider bought $691K of stockPositive▶
Henry Schein shares rose 4.5% to $72.61 on May 14 after Q1 2026 net sales climbed 6.3% to $3.37B and non-GAAP EPS rose 14.8% to $1.32. Adjusted EBITDA reached $289M and management reaffirmed full-year 2026 guidance of non-GAAP EPS $5.23-$5.37 and total sales growth of 3%-5%. On May 12, Director William Daniel purchased 10,000 shares for $691,900, a notable insider vote of confidence. Analysts trimmed targets - Baird lowered PT to $97 from $104 and UBS to $85 from $87. The stock trades 12.4% below the estimated fair value of $82.89.
May 14Henry Schein Q1 sales rise 6.3% with 8.1% EPS beat; multiple analysts cut price targets and Chairman Bergman to retire after 44 yearsMixed▶
Henry Schein reported Q1 2026 on May 5 with net sales of $3.37B (up 6.3% YoY) and non-GAAP diluted EPS of $1.32 (up 14.8% YoY), beating consensus by 8.4%. Management reaffirmed FY26 non-GAAP EPS guidance of $5.23-$5.37 and total sales growth of 3-5%. Value creation initiatives are expected to deliver $125M run-rate operating income improvement by year-end 2026 and over $200M cumulatively. The board will reduce to 10 directors after the May 21, 2026 annual meeting as founding director Stanley M. Bergman retires after 44 years and is named Chairman Emeritus. Director William Daniel purchased 10,000 shares for $691,900 in a notable insider buy. Multiple analysts cut price targets: Baird to $97 (from $104), Mizuho to $82 (from $88), UBS to $85 (from $87). Risk: medical segment softness offsetting dental and technology strength.
May 13Henry Schein beat Q1 with $3.4B revenue (+6.3%) and EPS of $1.32 (+8.4% beat), reaffirmed 2026 guidance, and Director William Daniel bought 10,000 shares for $691,900 on May 11.Mixed▶
Henry Schein reported Q1 2026 net sales of $3.4B, up 6.3% year-over-year, with non-GAAP EPS of $1.32 (8.4% above consensus), driven by dental and technology strength offsetting medical softness. The company repurchased ~1.6M shares at an average $77.64 for $125M and reaffirmed 2026 non-GAAP EPS guidance of $5.23-$5.37 with sales growth of 3%-5%. Director William Daniel purchased 10,000 shares on May 11 at $69.19 for $691,900, signaling insider confidence below current trading levels. Despite the beat, three analysts cut targets on May 7: Baird to $97 from $104, Mizuho to $82 from $88, and UBS to $85 from $87. The Board will shrink from 15 to 10 members after the May 21 annual meeting, with KKR holding a 16.4% stake noted in the proxy. Risks include medical segment softness and CEO transition execution.
May 12No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 11Henry Schein beat Q1 2026 estimates with sales up 6.3% to $3.37B and reaffirmed 2026 guidance with $125M run-rate cost savings by year-end.Mixed▶
Henry Schein reported Q1 2026 sales up 6.3% YoY to $3.37B, beating estimates, with non-GAAP EPS of $1.32, 8.4% above consensus. Global distribution sales grew 6.1% and U.S. dental merchandise sales rose 5.6%. The company reaffirmed 2026 guidance of 3-5% total sales growth and non-GAAP diluted EPS of $5.23-$5.37. Value creation initiatives are targeting $200M+ operating income improvement over the next few years, with a $125M run-rate by year-end 2026. Despite the beat, several analysts trimmed targets: Baird to $97 from $104, Mizuho to $82 from $88, UBS to $85 from $87.
May 8Beat Q1 earnings with $1.32 EPS and 6.3% revenue growth to $3.37B; $200M+ cost improvement expectedPositive▶
Henry Schein reported Q1 2026 with revenue of $3.37B (6.3% growth YoY) and non-GAAP EPS of $1.32, beating consensus of $1.20 by 6%. Adjusted EBITDA increased to $289M from $259M in Q1 2025. Value creation initiatives are expected to deliver over $200M operating income improvement over coming years with $125M run-rate by end of 2026. Company repurchased 1.6M shares for $125M at average price of $77.64. Frederick M. Lowery appointed as CEO on March 2, 2026, succeeding Stanley M. Bergman after 35 years. Full-year 2026 guidance reaffirmed: non-GAAP EPS $5.23-$5.37.
May 7Henry Schein Q1 2026 non-GAAP EPS of $1.32 beats by 8.4% as dental and cloud platforms accelerate growthPositive▶
Henry Schein reported Q1 2026 net sales of $3.37 billion, up 6.3% year-over-year but 1.2% below the $3.41 billion consensus estimate. Non-GAAP EPS of $1.32 exceeded consensus by 8.4%. Cloud-based practice management platforms including Dentrix Ascend and Dentally saw a 25% year-over-year increase in subscribers, with an AI-powered clinical workflow launch noted as key milestone. CEO Frederick Lowery emphasized continued market share expansion with independents and DSOs growing faster than the broader market. The company reaffirmed full-year 2026 guidance with non-GAAP EPS of $5.23-$5.37. Board announced size reduction following May 21 annual meeting, with Stanley M. Bergman retiring after 44 years. Mizuho lowered price target from $88 to $82 on May 7.
May 6Henry Schein Q1 2026 Earnings Beat Drives 8% Stock Surge; CEO Plans Operational OptimizationPositive▶
Henry Schein reported strong Q1 2026 earnings beating estimates with adjusted EPS of $1.32 (8.4% above consensus) and revenue of $3.37 billion, up 6.3% YoY. Growth driven by 2.5% internal sales growth, 0.7% from acquisitions, and 3.1% FX benefit. Adjusted EBITDA of $289 million exceeded estimates of $275.1 million with 8.6% margin. New CEO Frederick M. Lowery executing 100-day plan to sharpen operational execution, accelerate AI/software offerings, and leverage BOLD+1 platform. Full-year 2026 non-GAAP EPS guidance reaffirmed at $5.23-$5.37. Stock surged 8% post-earnings to $75.74 from $72.02.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| MCKMCKESSON | $773.91 | +0.97% | -1.2% | 15.2x | 0.35 | $92.1B |
| CORCENCORA | $280.20 | +5.56% | +1.4% | 13.4x | 0.65 | $51.6B |
| CAHCARDINAL | $223.87 | +11.59% | +0.4% | 16.8x | 0.54 | $47.0B |
| HSICHENRY | $81.88 | +11.40% | +1.1% | 12.4x | 0.82 | $8.4B |
| LLYELI | $1,119.42 | +7.47% | +5.4% | 23.4x | 0.48 | $928.9B |
| JNJJOHNSON | $237.09 | +2.31% | +1.2% | 18.2x | 0.26 | $557.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.